Breaking News
FONT-SIZE Plus   Neg
Share SHARE

GlaxoSmithKline Announces Regulatory Submission To FDA For Albiglutide

RELATED NEWS
Trade GSK now with 

GlaxoSmithKline plc (GSK: Quote, GSK.L) announced a regulatory submission to the US FDA for albiglutide, an investigational once-weekly treatment for adult patients with type 2 diabetes. GlaxoSmithKline intends to submit a regulatory application in the European Union in early 2013.

Albiglutide, a GLP-1 receptor agonist, is an investigational biological product for the treatment of type 2 diabetes designed for once-weekly subcutaneous dosing. Albiglutide is not yet approved as a treatment for type 2 diabetes or any other indication anywhere in the world.

Click here to receive FREE breaking news email alerts for GlaxoSmithKline PLC and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Fashion retailer Gap Inc. said Thursday after the markets closed that its second quarter profit rose 10% from last year, helped by higher sales and a gain from asset sale. The company's quarterly earnings per share, excluding items, also came in above analysts' expectations as did its quarter sales. Separately, Gap announced plans to enter India through franchise-operated Gap brand stores in 2015. While buying interest was somewhat subdued, stocks moved mostly higher over the course of the trading day on Thursday. The gains on the day extended the recent upward trend by the markets, lifting the S&P 500 to a new record closing high. Republicans have not found much to like about President Barack Obama's nearly six years in office, but the results of a new Washington Post-ABC News poll show that a vast majority support the president's decision to launch airstrikes in Iraq.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.